Patel Pawan D, Arora Rohit R
Department of Cardiology, Chicago Medical School, North Chicago, IL 60064, USA.
Vasc Health Risk Manag. 2008;4(4):819-24. doi: 10.2147/vhrm.s2841.
Chronic stable angina is a debilitating illness affecting at least 6.6 million US residents. Despite being optimally treated by pharmacotherapy and revascularization up to 26% of patients still experience angina. Diabetes mellitus is a common co-morbid condition in angina patients. Several new investigational medications are being tested for chronic angina. Advances in understanding of myocardial ischemia have prompted evaluation of a number of new antianginal strategies. In this review we discuss the utility of ranolazine, a recently approved novel antianginal agent and its efficacy in the diabetic patient population. In addition to its antianginal action in diabetic patients with chronic angina, ranolazine may have favorable effects on glycated hemoglobin levels.
慢性稳定性心绞痛是一种使人虚弱的疾病,影响着至少660万美国居民。尽管通过药物治疗和血运重建进行了最佳治疗,但仍有高达26%的患者会出现心绞痛。糖尿病是心绞痛患者常见的合并症。几种新的研究性药物正在针对慢性心绞痛进行测试。对心肌缺血认识的进展促使人们评估了许多新的抗心绞痛策略。在本综述中,我们讨论了雷诺嗪(一种最近获批的新型抗心绞痛药物)的效用及其在糖尿病患者群体中的疗效。除了对患有慢性心绞痛的糖尿病患者具有抗心绞痛作用外,雷诺嗪可能对糖化血红蛋白水平有有利影响。